The optimal dose of triptorelin for triggering final oocyte maturation in patients at high-risk for OHSS: a randomized clinical trial

被引：0

作者：

Lainas, G. T. ^{[1
]}

Bosdou, J. K. ^{[1
]}

Venetis, C. A. ^{[2
]}

Sfontouris, I. A. ^{[3
]}

Chatzimeletiou, K. ^{[1
]}

Zepiridis, L. ^{[1
]}

Makedos, A. ^{[1
]}

Daniilidis, A. ^{[1
]}

Mitsoli, A. ^{[1
]}

Savvaidou, D. ^{[1
]}

Lainas, T. G. ^{[3
]}

Tarlatzis, B. C. ^{[1
]}

Kolibianakis, E. M. ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Sch Med, Unit Human Reprod, Dept Obstet & Gynecol 1, GR-54006 Thessaloniki, Greece

[2] Univ New S Wales, Sch Womens & Childrens Hlth UNSW Med, Sydney, NSW, Australia

[3] EUGONIA, Eugonia Unit Assisted Reprod, Athens, Greece

来源：

HUMAN REPRODUCTION | 2015年 / 30卷

关键词：

agonist trigger; triptorelin dose; high risk for OHSS; oocyte maturity; OHSS prevention;

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

O-219

引用

页码：95 / 96

页数：2

共 50 条

[1] Is oocyte maturation rate associated with the dose of triptorelin used for triggering final oocyte maturation in high-risk for severe OHSS patients, undergoing ovarian stimulation.
Lainas, T. G.
Lainas, G.
Sfontouris, I.
Venetis, C.
Bosdou, J.
Chatzimeletiou, A.
Tarlatzis, B.
Grimbizis, G.
Kolibianakis, E.
HUMAN REPRODUCTION, 2019, 34 : 419 - 420
[2] Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas, G. T.
Lainas, T. G.
Sfontouris, I. A.
Chatzimeletiou, K.
Venetis, C. A.
Bosdou, J. K.
Tarlatzis, B. C.
Grimbizis, G. F.
Kolibianakis, E. M.
HUMAN REPRODUCTION, 2019, 34 (09) : 1770 - 1777
[3] GnRH agonist for triggering final oocyte maturation versus IVM in patients at risk of OHSS
Gidoni, Y. S.
Raziel, A.
Friedler, S.
Strassburger, D.
Hadari, D.
Kasterstein, E.
Ben-Ami, I.
Komarovsky, D.
Maslansky, B.
Bern, O.
Ron-El, R.
HUMAN REPRODUCTION, 2013, 28 : 339 - 339
[4] Recombinant vs. urinary human chorionic gonadotrophin (hCG) for triggering final oocyte maturation in patients at risk for ovarian hyperstimulation syndrome OHSS: a randomized clinical trial
Lainas, G.
Lainas, T.
Venetis, C.
Sfontouris, I.
Zorzovilis, I.
Petsas, G.
Bosdou, J.
Tarlatzis, B.
Kolibianakis, E.
HUMAN REPRODUCTION, 2016, 31 : 452 - 453
[5] BMI is not associated with oocyte recovery rate or maturation rate in high-risk for severe OHSS patients triggered with GnRH-agonist for final oocyte maturation
Sfontouris, I.
Lainas, G.
Lainas, T.
Bosdou, J.
Chatzimeletiou, A.
Grimbizis, G.
Kolibianakis, E.
HUMAN REPRODUCTION, 2019, 34 : 418 - 419
[6] OPTIMAL RECOMBINANT hCG DOSE FOR FINAL OOCYTE MATURATION TRIGGERING IN POOR RESPONDERS
Park, K. E.
Jee, B. C.
Suh, C. S.
Kim, K. C.
Lee, W. D.
Kim, S. H.
FERTILITY AND STERILITY, 2012, 98 (03) : S157 - S157
[7] Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: A prospective, clinical cohort study
Griesinger, Georg
Berndt, Henriette
Schultz, Laura
Depenbusch, Marion
Schultze-Mosgau, Askan
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2010, 149 (02) : 190 - 194
[8] REPEATED INJECTION OF GnRH AGONIST FOR TRIGGERING FINAL OOCYTE MATURATION IN PATIENTS AT HIGH RISK OF OHSS IN GnRH ANTAGONIST PROTOCOL: A PROSPECTIVE, COHORT STUDY.
Chen, S. -L.
Chen, X.
Ye, D. -S.
He, Y. -X.
Tao, T.
FERTILITY AND STERILITY, 2013, 100 (03) : S263 - S263
[9] GnRH agonist for triggering final oocyte maturation in patients with PCO at high risk for severe OHSS: factors predicting live birth in subsequent FRET cycles
Tarlatzi, T.
Bosdou, J.
Venetis, C.
Lainas, G.
Sfontouris, I.
Makedos, A.
Chatzimeletiou, K.
Zepiridis, L.
Mitsoli, A.
Savaidou, D.
Lainas, T.
Tarlatzis, B.
Kolibianakis, E.
HUMAN REPRODUCTION, 2016, 31 : 129 - 130
[10] GNRH AGONIST VERSUS HCG TO INDUCE FINAL OOCYTE MATURATION IN PATIENTS AT LOW RISK OF OHSS
Green, K. A.
Healy, M. W.
DeCherney, A. H.
Beall, A. S.
Chang, F. E.
Devine, K.
Hill, M. J.
FERTILITY AND STERILITY, 2018, 109 (03) : E28 - E28

← 1 2 3 4 5 →